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A B S T R A C T
Neurocognitive disorders are frequent among chronic kidney
disease (CKD) patients. Identifying and characterizing cognitive
impairment (CI) can help to assess the ability of adherence to
CKD risk reduction strategy, identify potentially reversible
causes of cognitive decline, modify pharmacotherapy, educate
the patient and caregiver and provide appropriate patient and
caregiver support. Numerous factors are associated with the de-
velopment and progression of CI in CKD patients and various
conditions can influence the results of cognitive assessment in
these patients. Here we review clinical warning signs that should
lead to cognitive screening; conditions frequent in CKD at risk
to interfere with cognitive testing or performance, including
specificities of cognitive assessment in dialysis patients or after
kidney transplantation; and available tests for screening and ob-
served cognitive patterns in CKD patients.
Keywords: chronic kidney disease, clinical assessment, cogni-
tive impairment, cognitive screening test, comprehensive
battery
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I N T R O D U C T I O N
Chronic kidney disease (CKD) is a major public health problem
with a high global incidence and prevalence, with important
multisystemic complications leading to poor outcomes and
high-cost treatments [1]. According to Kidney Disease:
Improving Global Outcomes, CKD is defined as abnormalities
of kidney structure or function present for >3 months with
implications for health. The following criteria determine the
diagnosis: decreased glomerular filtration rate (GFR; <60 mL/
min/1.73 m2) or evidence of kidney damage such as albumin-
uria, tubular disorders, urine sediment abnormalities, structural
deviations detected by histology or by imaging methods or a
history of kidney transplantation. The reduction of GFR and
increased albuminuria have a crucial role in the development of
complications of CKD, and for this reason the disease is
classified in five stages based on the GFR and risk levels are
subclassified according to albuminuria levels [1]. CKD stages
are associated with all-cause death, cardiovascular death, anae-
mia and bone and mineral disorders, among other complica-
tions [2]. The prevalence of CKD and cognitive impairment
(CI) both increase with age. Cognitive changes occur early in
CKD, when GFR decreases to<60 mL/min/1.73 m2 or even be-
fore [3, 4].
The latest version of the Diagnostic and Statistical Manual of
Mental Disorders defined neurocognitive disorder (NCD) as
primarily cognitive disorders, acquired and progressive [5].
Deterioration can affect one of the following six cognitive
domains: complex attention, executive function, learning and
memory, language, perceptual motor and social cognition. In
mild NCD [corresponding to the state usually called ‘mild cog-
nitive impairment’ (MCI)], the individual remains functionally
independent, while in major NCD (subsumes the entity called
‘dementia’), CI is severe enough to compromise social and/or
occupational functioning [6]. Cognitively impaired CKD
patients often exhibit executive dysfunction that would be
expected in vascular NCD, but CKD patients are also at higher
risk of Alzheimer’s disease and mortality compared with the
general population [7]. CI is associated with adverse outcomes
and financial and social costs, including caregiver burden. CKD
patients [especially when under renal replacement therapy
(RRT)] could benefit from cognitive screening. Identifying CI
in patients with CKD can help to assess the ability to adhere to
a CKD risk reduction strategy, identify potentially reversible
causes of dementia, modify pharmacotherapy, educate the pa-
tient and caregiver and provide appropriate patient and care-
giver support. The potential benefits of screening likely
outweigh the possible risks associated with identification, such
as negative reaction to the diagnosis or stigma resulting from a
diagnosis of dementia. We aim to review the specificities of clin-
ical assessment for cognitive disorders in CKD patients: clinical
warning signs that should lead to cognitive screening;
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conditions frequent in CKD that may interfere with cognitive
testing or performance, including specificities of cognitive as-
sessment in dialysis patients or after kidney transplantation;
and available tests for cognitive screening and observed cogni-
tive patterns in CKD patients.
Warning signs of cognitive decline in CKD patients
Neurological complications frequently become clinically evi-
dent in advanced stages of the disease, therefore early detection
and management of these conditions could reduce their impact
at later stages [8]. Of interest, subjective cognitive complaints
are not highly correlated with the presence of objective CI in
end-stage renal disease (ESRD), highlighting the importance of
periodic screening for early identification of CI that may lead to
targeted interventions and timely discussions with the patient
and his/her family [4, 9, 10]. Nephrologists and other clinicians
may rely on their clinical judgement to obtain appropriate
diagnoses. Of note, a previous study reported that mental
impairment among haemodialysis (HD) patients was poorly
recognized by healthcare providers/HD technicians, even
though they reported spending an average of 47 min with
each patient during each of the twice- or thrice-weekly
treatments [11].
History taking and physical examination in conjunction
with neuropsychological testing can accurately identify cogni-
tive declines. Caregivers and family often notice cognitive defi-
cits before they are apparent to clinicians. Therefore history
taking from both the patient and caregiver/family is important
for accurate reports on the onset, duration and severity of cog-
nitive and behavioural deficits, the presence of functional
impairments and other symptoms (e.g. sleep disturbance,
depression, etc.) or other events including unexplained falls or
confusion about medication [10, 12]. Of note, caregiver-
reported sleep disturbances are frequently associated with early
stages of dementia and might be considered as warning signs of
cognitive deterioration [13]. The examiner should look for focal
neurological deficits such as tremors, bradykinesia or rigidity
suggestive of previous stroke and signs of parkinsonism [10].
Assessment of functionality in everyday activities and mobil-
ity performance metrics such as the gait speed assessment could
also offer hints of cognitive decline. For instance, mobility per-
formance metrics that involved multifaceted coordination be-
tween different parts of neuropsychology, such as cumulated
posture duration and postural transition, could assist in dis-
criminating those with and without CI [14]. CI suspicion may
lead to a global and comprehensive patient assessment, espe-
cially screening for factors affecting cognitive performance.
Older CKD patients might benefit from a nephrology-tailored
comprehensive geriatric assessment including a cognitive as-
sessment [15].
Conditions affecting cognitive assessment in CKD
patients
Numerous factors can affect the results of cognitive assess-
ment and cause deviations from the ‘norm’ in the psychometric
definition. These factors should be considered when interpret-
ing results in patients with CKD.
Demographic and psychosocial factors . Demographic fac-
tors such as lower education status, gender and age are key fac-
tors affecting the results of cognitive testing in the general
population. Advancing age, a lower educational level and fe-
male gender are associated with poorer performance [15].
However, the impact of such factors on cognitive testing among
CKD patients is limited [16]. Psychosocial factors including so-
cial support, socio-economic care and access to healthcare were
also found to influence cognitive functioning in the general
population. Similarly, data are limited regarding such factors
and CI in this patient population. Of note, marital status, reli-
gious activity and employment were found to influence psycho-
social adjustment to dialysis treatment and the risk for
developing depression among dialysis patients [17].
Drug-related factors, sleep and depression. Multiple med-
ications are required in CKD patients and the optimal dosing of
several medications is unclear, therefore these patients could be
more susceptible to potential adverse drug effects and interac-
tions between medications [18]. Some medications are associ-
ated with CI in CKD patients, such as H1-receptor antagonists
and opioids, probably because of their anticholinergic effect
[19]. If possible, unnecessary or ineffective medications with
central nervous system activity should be discontinued [19]. In
addition, sleep disturbances are often underdiagnosed and
undertreated in CKD patients, which can impact cognitive
function (e.g. memory and concentration), leading to excessive
daytime fatigue and sleepiness, impairing cognitive abilities di-
rectly [20]. Sleep-disordered breathing (sleep apnoea) was also
found to affect cognitive testing in CKD patients [21]. Lastly,
depression was found to be highly prevalent in dialysis patients
compared with the general population, with most studies esti-
mating that 20–30% of such individuals are depressed [22, 23].
Even though depression is relatively common in patients with
all stages of CKD, it remains significantly underdiagnosed [20,
24]. Depression may influence the results of cognitive testing
and hence assessment of depression and anxiety should be part
of all neuropsychological evaluations [25].
Factors associated with impaired cognitive performance
Biologic intrinsic-related factors. Anaemia has been linked
with cognitive deficiency in both CKD and the elderly [26].
This might be due to a decreased blood haemoglobin concen-
tration that leads to reduced oxygen delivery to the brain, with a
detrimental effect on brain metabolism, or could be because
once the blood haemoglobin concentration declines, cerebral
blood flow increases from normal to high levels, resulting in in-
creased distribution of uraemic toxins to the brain. Of interest,
early small-scale studies have shown cognitive improvement
with the treatment of anaemia in CKD patients; however, it
remains undetermined whether this is because of the improve-
ment in the blood count or due to an independent effect of sup-
plementation with erythropoiesis-stimulating agents (ESAs)
[27]. This observation was not confirmed in more recent large-
scale studies, where ESAs have not shown the expected benefi-
cial clinical cognitive effects in CKD patients. Also, putative
neurotoxins, including parathyroid hormone and by-products
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of nitrogen metabolism, have also been mentioned as possible
mediating factors of CI in CKD, but the underlying mecha-
nisms are not well understood [28]. Interestingly, recent find-
ings on the role of the glymphatic system, which clears the
brain of protein waste products, primarily during sleep, offer
pathophysiological hypotheses in CKD patients [13]. The link
between uraemic toxins and cognitive disorders is described in
detail in a parallel article in this supplement (Liabeuf et al.,
NDT 2021). Evidence data about albuminuria as a risk factor
for CI and dementia are also detailed in another article in this
supplement (Hafez et al. NDT 2021).
Amino acids. Amino acids have a multifaceted physiological
significance in addition to being the main building material in
protein synthesis. Plasma levels of homocysteine, cysteine
and cysteine sulfinic acid are elevated in uraemia and the
percentages of protein-bound homocysteine and cysteine are
higher in uraemic dialysis patients than in conservatively
treated patients. Elevated homocysteine levels have been associ-
ated with impairment and decline on tests of cognitive function.
Hyperhomocysteinaemia and low taurine levels are probably
involved in the pathogenesis of concomitant cardiovascular
and cerebrovascular diseases in patients with CKD.
Supplementation with vitamin B (combinations containing B6,
B12 and folic acid) in the Homocysteine Study to some extent
corrected hyperhomocysteinaemia but had no effect on cogni-
tive function [29]. The lack of a positive effect can be attributed
to comorbidities [29]. Increased amounts of aspartate may con-
tribute to ageing-related CI by facilitating excitotoxicity [30].
Vascular-related factors. Large prospective studies have
indicated several vascular factors, including older age, hyperten-
sion, diabetes mellitus and dyslipidaemia, as risk factors for
dementia in the general population [31]. Dialysis and CKD
populations share most of these same risk factors for CI.
Despite there is greater prevalence of traditional vascular risk
factors [e.g. hypertension, diabetes mellitus, hyperlipidaemia,
cigarette smoking, atrial fibrillation (AF) and myocardial
infarction] and cardiovascular disease (CVD) among CKD
patients, studies to date have failed to establish a direct link be-
tween any of these factors and the presence of cognitive dys-
function in patients with CKD [11, 28, 32, 33]. This implies that
other factors may be implicated in the occurrence of CI.
A possible role has been suggested for novel vascular risk
factors such as elevated levels of inflammatory mediators, which
have been observed in CKD patients, highlighting the possibil-
ity of an association between inflammatory markers and all-
cause dementia, as reported in the general population [34, 35].
Likewise, elevated levels of prostaglandin D2 synthase, a media-
tor of inflammation, could induce neural apoptosis in dialysis
patients [36]. Higher C-reactive protein levels were also
reported in dialysis patients [37] and have been linked to CI in
the general population [38].
The significance of silent cerebrovascular disease is
highlighted by studies that showed an association between CI
and silent brain infarction, which was most commonly attribut-
able to subcortical lacunar infarcts in the general population
[39]. Silent brain infarction has been shown to be an
independent risk factor for future cerebral and vascular mor-
bidity and incident dementia in both CKD/dialysis patients and
the general population [39–41]. Previous magnetic resonance
imaging studies have indicated that clinically silent white matter
hyperintensities of presumed vascular origin appear in50% of
patients with CKD [41, 42] and relate to deficits in the cognitive
domains of executive function and processing speed, suggesting
a subcortical, vascular pattern of CI. Notably, established risk
factors for white matter disease in CKD include advanced age,
hypertension and smoking [41]. Other lesions may be involved
besides lacunar infarcts and white matter hyperintensities, such
as brain microbleeds or atrophy related to cerebral small vessel
disease.
Cardiac arrhythmias. CVDs frequently occur in CKD
patients [43]. CKD is combined with haemodynamic changes,
which might further contribute to the negative changes in car-
diac structure. In particular, it has been reported that 50% of all
patients affected by CKD Stages 4 and 5 have CVD and cardio-
vascular mortality accounts for almost 50% of all deaths in
CKD patients (Stages 4 and 5) compared with 26% of age-
matched healthy control subjects [43]. Focusing on myocardial
alterations, left ventricular hypertrophy (LVH) is present in al-
most 30% of CKD patients, a prevalence that increases up to
70–80% in CKD Stage 5 patients [44]. LVH was associated with
incident dementia due to the strong association with increased
systemic blood pressure, followed by impaired ventricular fill-
ing, left ventricular diastolic dysfunction, whole body hypoper-
fusion as well as myocardial structural changes such as a dilated
atrial chamber, with an enhanced probability to develop AF
[45]. Such negative cardiac structural changes are often associ-
ated with a high ventricular rate [46], which again is responsible
for brain hypoperfusion and sudden death. Among the cardiac
arrhythmias, AF is most common, estimated to occur in 44% of
CKD (Stages 3–5) patients [47]. AF is one of the treatable cogni-
tive risk factors in CKD. Direct evidence of the strong relation-
ship between AF and cognitive decline is also provided by the
evidence that anticoagulation and ablation, but not anti-
aggregation, are helpful therapeutic tools for treating AF and
preventing cognitive decline [48].
Pulse wave velocity. Arterial stiffness can cause microvascu-
lar damage in the brain due to an increased impact of pulsatility
on the microvasculature, which possibly alters brain structure
or cognitive functioning. Several studies in CKD patients have
shown an association between increased pulse wave velocity
and CI (global cognition or executive dysfunction), pointing to
the role of large artery damage in this complex process [49].
Specificities of cognitive assessment for patients under
RRT
Dialysis. One important aspect for clinicians and researchers
involved in cognitive testing of patients with CKD is the timing:
when, during the day, should a cognitive test be administered?
This question is especially crucial for HD patients. There is a
theoretical risk that administering tests during the dialysis ses-
sion may lead to altered performance due to the lack of privacy,
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the ongoing extracorporeal treatment (with modifications in
electrolyte and water content of the plasma), the forced immo-
bilization, the psychologically stressful situation and the effect
of accumulated toxins. Furthermore, these variables make com-
parisons with a control population more difficult, as non-HD
control subjects are tested in completely different conditions.
To empirically test this problem, Murray et al. [50] observed
that the Mini–Mental State Examination (MMSE) score was re-
duced by 1 point (4%) when administered before HD compared
with the score achieved 1 h after treatment or the day after [50].
This result has been known since the 1970s and confirmed sev-
eral times [51]. Unsurprisingly, the lower MMSE scores do not
improve during the first hour of HD [50, 52]. Likewise, imaging
studies [53] and electroencephalogram (EEG) records [54] have
shown variations in brain activity according to the timing of the
dialysis session.
This timing parameter seems less problematic regarding
cognitive testing in peritoneal dialysis (PD), due to it being an
at-home treatment and the frequent dialytic exchanges (often
on the order of two to three per day, every day). Indeed, one
major difference between HD and PD is the intermittent nature
of the HD treatment compared with the almost continuous PD
treatment. An EEG study confirmed that PD brain activity is
more stable compared with the great changes occurring before
and after HD (with better EEG after HD) [54]. Therefore, stud-
ies adopt an off-dialysis timing (with an interval of at least 2 h
from the last session) [55]. New methods of HD (such as noc-
turnal HD or the use of a cooled dialysate) are expected to re-
duce the burden of sessions on neurocognitive function and
quality of life.
These data suggest that the cognitive performance in HD
patients is not stable and may constantly decrease as a function
of the elapsed time from the last dialysis session. This may
greatly impinge on interpretation of the results. Therefore we
recommend testing patients at least 1 h after the HD session,
particularly if a control group without HD is used. The testing
time for PD should be the same as for the general population.
We also recommend establishing appropriate timing in re-
search studies in case patients with CKD are included.
Kidney transplantation. Cognitive function has been
shown to improve after kidney transplantation, specifically in
psychomotor speed, attention, visual planning, learning and
memory and abstract thinking [56]. Nevertheless, CI remains
more frequent in kidney transplant (KT) patients than in the
general population and is associated with frailty measured using
the physical frailty phenotype developed [57, 58]. Frail KT
recipients are at a higher risk of immunosuppression intoler-
ance and mortality than non-frail patients [58]. Post-KT frailty
and cognitive performance are likely dynamic. On the one
hand, frailty initially worsens in the first month post-KT, but
then improves by 3 months post-KT; on the other hand, cogni-
tive performance, assessed by the modified MMSE (3MSE),
tends to improve in the first 3 months post-KT [57, 58]. More
research is needed to differentiate if post-KT issues, like wound
healing, immunosuppression and infections, may affect the re-
versal of frailty and CI after KT.
Of note, in animal models, stress and corticosteroids are as-
sociated with memory impairment and both reversible and irre-
versible changes in the hippocampus. Clinical studies observed
that exposure to exogenous corticosteroids can change mood
and declarative memory, but a negative effect on cognition was
modest [59]. Psychopathological signs frequently observed in-
dicate that corticosteroids may also induce functional disorder
of additional brain regions (e.g. frontal and temporal lobes),
which are important for cognitive and emotional processing
[60]. In order to minimize the impact of high-dose steroids and
operative procedures on cognition, we recommend performing
an assessment at least 1 month after transplantation.
Perceived and measured cognition in KT patients differs. In
157 KT patients assessed by trained medical personnel, per-
ceived cognition scores weakly correlated with Montreal
Cognitive Assessment (MoCA) scores [61]. Therefore, as in
other CKD patients, efficient cognitive screening in KT patients
relies on objective screening tests. However, it is still not fully
clear which screening tool should be used. Recent studies ob-
served discrepancies in the prevalence of CI in KT patients,
probably because the tests were different (MoCA, DemTect
tool) [62].
Calcineurin inhibitors (CNIs) have a known side effect of
neurotoxicity [63]. A small study observed that attention and
working memory were impaired in KT patients treated with
sirolimus or tacrolimus, while performance of cyclosporine-
treated subjects was similar to healthy volunteer controls. Long-
term effects of CNI on cognition and physiopathology are not
well understood [63]. Further studies may establish the optimal
timing for cognitive assessment after KT and identify an opti-
mal screening test in this specific population.
Screening tests
Today, most scientific societies, including nephrology, rec-
ommend cognitive assessment in individuals with cognitive
complaints and in individuals whose caregivers notice symp-
toms that may indicate the presence of CI, especially when there
are difficulties in daily functioning. Various screening tests are
commonly used in daily clinical practice to assess cognitive sta-
tus [64] (see Table 1).
There is no consensus on which screening instrument
should be used to identify NCD (major or mild) in people with
CKD. Rather, the screening methods used reflect the availability
of tests in a given language or the habits of the examinees.
In clinical practice, two main screening tests of CI are used,
the MMSE and, more recently, the MoCA. As in other diseases
[65], the superiority of the MoCA, which also assesses executive
functions, and is especially sensitive to brain dysfunction com-
pared with the MMSE, has been examined in several studies in
CKD patients. Focusing on the few studies using a comprehen-
sive neuropsychological battery as a gold standard and receiver
operating characteristics curve analysis, the area under the
curve (AUC) did not significantly differ across tests [66, 67].
This indicates that the sensitivity of both screening tests does
not differ greatly, although the small to moderate sample sizes
require careful conclusion. From our point of view, the impor-
tant conclusion from these studies is that the sensitivity of both















L user on 22 D
ecem
ber 2021
Table 1. Examples of psychometric tests used in CKD patients
Examples of tests Details of test Function assessed Use in
CKD
Global cognition
MMSE 30-point test (orientation, attention and calculation, mem-
ory, language and visuospatial abilities)
Screening of global CI Yes
MoCA 30-point test (visuospatial abilities, executive functions,
memory, attention, language, abstract reasoning and
orientation)
Screening of global CI (including
executive functions)
Yes
CDT Non-verbal test. The patient is asked to draw a clock face







Boston Naming Test Name objects shown in 60 black-and-white line drawings.
Items are ordered according to their ability to be named,




Cancellation test Lines, circles, letters bells or stars are drawn in random
positions on a sheet of paper (A4) and presented to pa-
tient, who is asked to cancel or cross out the target
Visual neglect, response inhibi-
tion, motor perseveration and
attention
Yes
Judgement of line orientation 30-item test in which the patient is asked to match two an-
gled lines to a set of 11 lines that are arranged in a semi-




Patient is asked to copy a complex geometrical figure Complex visuospatial
constructional ability
Yes
Wechsler Adult Intelligence Scale (WAIS)
block design
Timed subtest of the WAIS. Identical blocks with surfaces
of solid red, surfaces of solid white and surfaces that are
half-red and half-white are presented to the patient. The
patient is asked, using an increasing number of blocks, to
replicate a pattern that the test administrator presents to
the patient
Visuospatial and organizational




Free and Cued Selective
Recall Test (FCRST)
The test is based on 12 pictorial stimuli. The patient is
asked to identify pictured items (e.g. grapes and vest) in
response to category cues (fruit and clothing). In the test
phase, subjects are asked to recall the items they learned
(free recall). The category cues are used to prompt recall




California Verbal Learning Test Patient is asked to recall List A (16 words) 5 times. List B
(interference, 16 words) is administered after List A for
one trial. Short-delay free recall and cued recall are ad-
ministrated after List B. A long delay follows the short-





Baddeley Door Test The patient views photographs of 12 doors for 3 s each.
Immediately thereafter, the patient tries to identify the
door from the study list among 12 arrays of 4 doors each
Visual memory Yes
Rey-Osterrieth Complex Figure
Test (3 min recall)
The patient is asked to reproduce from memory the com-
plex geometric figure he copied after a short delay
(3 min) and then a long delay (30 min)
Visual memory Yes
Executive functions and action speed
TMT Part A requires an individual to draw lines sequentially
connecting 25 encircled numbers distributed on a sheet
of paper. In Part B the patient must alternate between
numbers and letters (1-A-2-B-3-C)
Visuomotor speed, visual
attention (TMT Part A) and
task switching (TMT Part B)
Yes
The Stroop Colour and
Word Test
First, the subject is required to read names of colours
printed in black ink. Second, the subject names different
colour patches. Third, he/she is required to name the col-
our of the ink instead of reading the word (colour words




Semantic and literal fluency The patient is given 1 min to produce as many words as
possible within a semantic category or starting with a
given letter
Lexico-semantic knowledge,
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screening tests is usually <80%, which appears to be moderate
[66–68].
Regarding other screening tests, the Clock Drawing Test
(CDT), the digit span backward and the fist-edge-palm test
showed similar performance in identifying MCI in this popula-
tion when compared with the MoCA (24/30 patients) [69]. In
a recently published study, Drew et al. [67] compared the pre-
dictive ability of MMSE, 3MSE, MoCA, Trail Making Test
(TMT) Part B, Mini-Cog Test and the Digit Symbol
Substitution Test performance for identifying severe CI among
patients with HD. The MoCA had the highest overall predictive
ability for severe CI (AUC 0.81). The score of 21/30 patients
had a sensitivity of 86% and specificity of 55% for severe im-
pairment, with a negative predictive value of 91%. The TMT
Part B and Digit Symbol Substitution Test also performed rea-
sonably well (AUCs 0.73 and 0.78, respectively). The other tests
had lower predictive performances.
Self-reported cognitive assessment methods (e.g. MAC-Q)
are also available, but these are based primarily on observations
of memory deficits and may not have sufficient diagnostic sen-
sitivity in people with CKD. Despite some limitations, self-
reported assessment of instrumental activities of daily living
Table 1. Continued
Examples of tests Details of test Function assessed Use in
CKD
WAIS Digit Symbol Substitution
subtest
Timed subtest of the WAIS. The test involves a key
consisting of numbers (1–9), each paired with a unique
symbol. Below the key is a series of numbers (1–9) in
random order. The subject is then allowed 90 s to fill in







The subject is given a set of four stimulus cards, each differ-
ent from the other in terms of colour, shape or number.
The participant is asked to accurately sort every response
card with one of four stimulus cards but not how to
match. The administrator provides simple feedback
(right or wrong) based on a predetermined rule
Abstract reasoning, mental
flexibility and problem solving
Yes
Inventory of the Behavioural
Dysexecutive Syndrome
Structured interview of an individual assessing changes





Patient or relatives’ complaints
Functional impairment 
Confusion about medication
Unexplained falls, decreased 
mobility performance 
















Pulse wave velocity 
Factors associated with










KT: > 1 month
 after KT
Collaboration between nephrologists, neurologists, neuropsychologists, geriatricians, and general practitioners
CDT: Clock drawing test
HD: Hemodialysis
KT: Kidney transplant
MMSE: Mini mental state examination
MoCA: Montreal cognitive assessment
PTH: Parathyroid hormone
PD: Peritoneal dialysis




















FIGURE 1: Integrating CKD in NCDs.
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remains useful in determining the cognitive function of a pa-
tient. In case it is not possible to examine the patient in person,
it is advisable to use tools that allow for assessment by the care-
giver. The AD8 scale or Informant Questionnaire on Cognitive
Decline in the Elderly are recommended. Even if physicians do
not frequently use these modalities in daily practice, they can be
useful for epidemiologic studies. It is worth noting that most of
these cognitive tests were developed and validated in the ageing
population, affected by physiological decline in both brain and
renal function.
From a practical point of view, we propose using one of
the main screening tests (the MoCA or MMSE) with education-
(both tests) and age-adjusted (MoCA) cut-offs computed using
normative data from the population of the country. Future
studies are required to identify an optimal screening test and
cut-off for CKD patients.
Cognitive pattern in CKD patients
The diagnosis of mild NCD and mild dementia (which is the
present targeted stage of diagnostics) requires comprehensive
neuropsychological assessment performed by a neuropsycholo-
gist. In addition to a positive diagnosis, comprehensive assess-
ment determines the cognitive pattern, which constitutes a
central cue for the aetiological diagnosis. The choice of tests
composing the battery is determined by the clinical context in
order to improve sensitivity. It usually includes tests assessing
instrumental functions (language, visuospatial and constructive
abilities), episodic memory, action speed and executive func-
tions assessed both at the cognitive (i.e. tests) and behavioural
(i.e. semistructured heteroquestionnaires that include social
cognition) levels. Such a battery is usually not used for diagnos-
tic purposes in patients with clear impairment on screening
tests (e.g. MMSE <18 or MoCA<14); it should be interpreted
using country-related norms and specific procedures to im-
prove diagnostic accuracy [70].
The pattern of CI in CKD is not definitely established.
Berger et al. [4] systematically reviewed CI in CKD patients [es-
timated GFR (eGFR)<60 mL/min/1.73 m2] without RRT, in-
cluding 44 cross-sectional and cohort studies with 51 590
participants in the final meta-analysis. Cognitive domains were
not assessed with the same frequency in the studies: attention
and action speed (referred to as ‘orientation and attention’ in
the article; 28 studies), global cognition (25 studies), memory
(16 studies), executive functions (15 studies), construction and
motor praxis (11 studies), language (9 studies), concept forma-
tion and reasoning (6 studies) and perception (1 study). CKD
patients (eGFR<60 mL/min/1.73 m2) performed worse than
control groups in almost all cognitive domains except percep-
tion, construction and motor praxis. The study of Puy et al. [66]
formally assessed test sensitivity in 40 patients and showed that
four of the tests had a Cohen’s d index0.8: TMT Part B, Digit
Symbol Substitution Test, literal fluency and the groupe de re-
flexion pour l’evaluation des fonctions eXécutives (GREFEX)
inventory of the behavioural dysexecutive syndrome. This is
accounted for by the cognitive pattern with prominent impair-
ment of action speed (also called psychomotor speed
or processing speed) and cognitive and behavioural executive
functions. Anxiety and depression symptoms were also
common [66].
Cognitive decline occurs early in CKD and its frequency has
been observed with different rates across cognitive domains
according to GFR decline in these cross-sectional studies [4].
Interestingly, in studies assessing cognitive function in HD
patients, the frequency of every cognitive domain measurement
has the same ranges as in patients without RRT, from the most
frequent (with the most frequent test used): orientation and at-
tention (with TMT Parts A and B), global cognition (MMSE),
memory (Weschler Memory Scale), construction and motor
(Clock and Grooved Peg Board), executive function (Stroop
test), concept and reasoning (progressive matrices), language
(Hopkins Verbal Learning Test) and perception (Haltstead–
Reitan Neuropsychological Battery) [71]. Executive functions
and orientation and attention are the most frequently affected
domains in HD patients, even if their performance is poorer
than controls in other domains [51, 71]. The cognitive pattern
seems to be different in PD patients, with less impaired execu-
tive function [55].
These studies converge towards a prominent impairment of
three neuropsychological domains (action speed, cognitive and
behavioural executive functions) followed by impairment of
language and episodic memory [4, 51, 66, 71]. Such a cognitive
pattern is close to that of the two leading causes of CI, vascular
CI and Alzheimer’s disease. Based on this review, future re-
search may establish test sensitivity and cognitive patterns in a
large and representative population of CKD patients, including
full aetiological workup.
C O N C L U S I O N
Cognitive disorders are a frequent issue in patients with CKD.
Clinical assessment of CI in this population involves many spe-
cific conditions, as can be seen in Figure 1. Although much is
known, gaps in knowledge remain in this area. Further research
needs to be done, including the establishment of cognitive test
sensitivity for the CKD and KT populations, a description of
cognitive patterns and the establishment of optimal timing for
cognitive assessment in dialysis patients and after KT, among
others. Further research may be useful to provide guidelines for
clinicians, as comprehensive clinical assessment and aetiological
workup will help to provide suitable therapeutic management
taking into consideration CKD specificities.
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